We are live on ! Find out more
IPSC icon

Century Therapeutics

72 hedge funds and large institutions have $36.8M invested in Century Therapeutics in 2024 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more call options, than puts

Call options by funds: $10K | Put options by funds: $2K

200% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 10

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

50% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 10

7% more funds holding

Funds holding: 6772 (+5)

3.99% less ownership

Funds ownership: 46.8%42.81% (-4%)

46% less capital invested

Capital invested by funds: $67.8M → $36.8M (-$31M)

Holders
72
Holders Change
+5
Holders Change %
+7.46%
% of All Funds
0.95%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
15
Increased
30
Reduced
10
Closed
10
Calls
$10K
Puts
$2K
Net Calls
+$8K
Net Calls Change
+$10K
Name Holding Trade Value Shares
Change
Change in
Stake
AllianceBernstein
51
AllianceBernstein
Tennessee
$20.2K
SG Americas Securities
52
SG Americas Securities
New York
$20K +$4.5K +3,302 +21%
T. Rowe Price Associates
53
T. Rowe Price Associates
Maryland
$16K
Prudential Financial
54
Prudential Financial
New Jersey
$15.3K
New York State Common Retirement Fund
55
New York State Common Retirement Fund
New York
$13.9K
ProShare Advisors
56
ProShare Advisors
Maryland
$13.3K +$17.9K +13,180 New
VPIM
57
Vanguard Personalized Indexing Management
California
$10.3K +$13.9K +10,214 New
FFS
58
Founders Financial Securities
Maryland
$10.1K
TRCT
59
Tower Research Capital (TRC)
New York
$9.91K +$3.69K +2,709 +38%
BNP Paribas Financial Markets
60
BNP Paribas Financial Markets
France
$9.89K +$13.3K +9,792 New
Royal Bank of Canada
61
Royal Bank of Canada
Ontario, Canada
$7K +$2.65K +1,943 +36%
Legal & General Group
62
Legal & General Group
United Kingdom
$4.02K
California State Teachers Retirement System (CalSTRS)
63
California State Teachers Retirement System (CalSTRS)
California
$3.36K
CS
64
Clear Street
New York
$3.13K +$4.22K +3,100 New
SCM
65
Sterling Capital Management
North Carolina
$1.6K +$1.96K +1,443 +988%
AB
66
Amalgamated Bank
New York
$1K
Carson Wealth (CWM LLC)
67
Carson Wealth (CWM LLC)
Nebraska
$1K +$1.88K +1,379 +1,393%
Nisa Investment Advisors
68
Nisa Investment Advisors
Missouri
$987 +$1.15K +841 +618%
AIP
69
Ameritas Investment Partners
Nebraska
$914
MSFP
70
Mark Sheptoff Financial Planning
Connecticut
$505
Osaic Holdings
71
Osaic Holdings
Arizona
$363 -$994 -730 -67%
SS
72
SBI Securities
Japan
$283 +$381 +280 New
BC
73
Boxer Capital
California
-$6.67M -3,900,000 Closed
Adage Capital Partners
74
Adage Capital Partners
Massachusetts
-$2.26M -1,322,751 Closed
OCA
75
Octagon Capital Advisors
New York
-$1.14M -666,825 Closed

IPSC Hedge Fund Activity: Q4 2024 in Review

72 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Century Therapeutics (IPSC) for Q4 2024, worth a combined $36.8M — down 46% from $67.8M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new IPSC positions and 10 closed out — a net gain of 5 holders — while 30 added to existing stakes and 10 trimmed.

The largest buyer was Casdin Capital, adding an estimated $2.69M. The largest seller was Morgan Stanley, cutting an estimated $2.72M.

  • 72 institutional investors held Century Therapeutics (IPSC) as of Q4 2024, up from 67 in Q3 2024.
  • Funds reported $36.8M of Century Therapeutics stock for Q4 2024, down 46% quarter-over-quarter.
  • 15 funds opened new Century Therapeutics positions in Q4 2024 and 10 closed out, a net change of +5 holders.
  • The largest Century Therapeutics buyer in Q4 2024 was Casdin Capital, an estimated $2.69M added.
  • The largest Century Therapeutics seller in Q4 2024 was Morgan Stanley, an estimated $2.72M sold.

Based on aggregated 13F filings for Q4 2024.